Cargando…

Emergence of Omicron sub-variant BA.2: Is it a matter of concern amid the COVID-19 pandemic?

Detalles Bibliográficos
Autores principales:	Dhawan, Manish, Priyanka, Choudhary, Om Prakash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IJS Publishing Group Ltd. Published by Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860472/ https://www.ncbi.nlm.nih.gov/pubmed/35202859 http://dx.doi.org/10.1016/j.ijsu.2022.106581

Ejemplares similares

Implications of COVID-19 vaccine boosters amid the emergence of novel variants of SARS-CoV-2
por: Dhawan, Manish, et al.
Publicado: (2022)

Emergence of omicron variant's sublineages BA.4 and BA.5: risks assessment and possible countermeasures
por: Dhawan, Manish, et al.
Publicado: (2022)

Russo-Ukrainian war amid the COVID-19 pandemic: Global impact and containment strategy
por: Dhawan, Manish, et al.
Publicado: (2022)

Omicron SARS-CoV-2 variant: Reasons of emergence and lessons learnt
por: Dhawan, Manish, et al.
Publicado: (2022)

The recently emerged BA.4 and BA.5 lineages of Omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic – Correspondence
por: Mohapatra, Ranjan K., et al.
Publicado: (2022)

Vaccine inequity and hesitancy: Dual factors in the emergence of novel SARS-CoV-2 variants
por: Dhawan, Manish, et al.
Publicado: (2021)

A rapid surge of the Omicron variant’s sublineages BQ.1/BQ.1.1: A matter of worry amid the crucial trajectory of the COVID-19 pandemic
por: Dhawan, Manish, et al.
Publicado: (2023)

NeoCoV: A foresight of the next possible pandemic
por: Dhawan, Manish, et al.
Publicado: (2022)

Omicron variant (B.1.1.529) of SARS-CoV-2: Threat assessment and plan of action
por: Choudhary, Om Prakash, et al.
Publicado: (2022)

Antiviral pills: A potential game-changing therapy against COVID-19
por: Dhawan, Manish, et al.
Publicado: (2022)

Will the next spillover pandemic be deadlier than the COVID-19?: A wake-up call
por: Choudhary, Om Prakash, et al.
Publicado: (2022)

SARS-CoV-2 and Influenza A virus: Dual diagnostics and vaccines
por: Saied, AbdulRahman A., et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational impacts, concerns, and the possible solutions
por: Islam, Fahadul, et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection
por: Sukaina, Mahnoor, et al.
Publicado: (2022)

Emergence of monkeypox: Risk assessment and containment measures
por: Dhawan, Manish, et al.
Publicado: (2022)

Deltacron: Apprehending a new phase of the COVID-19 pandemic
por: Maulud, Sazan Qadir, et al.
Publicado: (2022)

Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks
por: Dhawan, Manish, et al.
Publicado: (2022)

Emergence of novel omicron hybrid variants: BA(x), XE, XD, XF more than just alphabets
por: Thakur, Pryanka, et al.
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Marburg virus disease outbreak amid COVID-19 pandemic: an emerging concern in Ghana, West Africa
por: Roy, Shubhajeet, et al.
Publicado: (2023)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Monkeypox outbreak: New zoonotic alert after the COVID-19 pandemic
por: Sharma, Amit, et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Evaluation of cross-neutralizing antibodies in children infected with omicron sub-variants
por: Peng, Weiyu, et al.
Publicado: (2023)

Severity of Omicron BA.5 variant and protective effect of vaccination: national cohort and matched analyses in Scotland
por: Robertson, Chris, et al.
Publicado: (2023)

The Omicron subvariant BA.2: Birth of a new challenge during the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection
por: Boucau, Julie, et al.
Publicado: (2022)

Emergence of Omicron BA.2.12.1 in Pakistan: What does it mean for the South Asian nation?
por: Awan, Hashir Ali, et al.
Publicado: (2022)

Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Vaccine efficacy against COVID-19: A foresight on the host-associated factors
por: Priyanka, et al.
Publicado: (2021)

Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa
por: Wolter, Nicole, et al.
Publicado: (2022)

Evasion of neutralising antibodies by omicron sublineage BA.2.75
por: Sheward, Daniel J, et al.
Publicado: (2022)

Protection against Reinfection with the Omicron BA.2.75 Subvariant
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Increased immune escape of the new SARS-CoV-2 variant of concern Omicron
por: Hu, Jie, et al.
Publicado: (2022)

Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5
por: Tan, Chee-Wah, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a1lq5vg5euvnc0b888nvtf1koq